Anlotinib Clinical Trial
Official title:
SHR-1210, a Novel Anti-PD-1 Antibody, in Combination With Anlotinib As Second-line or Above Treatment in Patients With Advanced or Metastatic Esophageal Squamous Cell Cancer: a Phase II Study
This study was designed to explore the clinical efficacy of SHR-1210 in combined with Anlotinib in the treatment of second- or above- line advanced or metastatic esophageal squamous cell cancer patients, in order to find a better therapy strategy for esophageal squamous cell cancer patients.
This is a prospective, phase II, single-arm clinical trial. Advanced or metastatic esophageal squamous cell cancer(ESCC) patients progressed after 1st systematic treatment are treated with SHR-1210 and Anlotinib. SHR-1210 was given intravenously(200mg d1 Q2w), combined with Anlotinib orally, 12 mg d1-14 Q3w. The hypothesis: The objective response rate in SHR-1210 combined with Anlotinib can reach 40% as second-line or above treatment of advanced or metastatic ESCC patients. The primary endpoint is objective response rate (ORR) and the secondary endpoint is disease control rate (DCR), overall survival (OS), progression-free survival (PFS), and safety of this regimen. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06048315 -
A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs With the Combination of Enrotinib and Paclitaxel Monoclonal Antibody
|
Phase 3 | |
Recruiting |
NCT04116918 -
Efficacy and Safety of the Combination of Anlotinib and JS001 in EGFR-TKI Resistant T790M-Negative NSCLC
|
||
Recruiting |
NCT04566952 -
Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer
|
Phase 2 | |
Not yet recruiting |
NCT05030077 -
Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma
|
Phase 2 | |
Recruiting |
NCT05602415 -
Anlotinib and Radiotherapy in Resectable Soft Tissue Sarcoma
|
Phase 2 | |
Withdrawn |
NCT04620473 -
Anlotinib Hydrochloride Combined With Capeox in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer
|
Phase 2 | |
Recruiting |
NCT04803851 -
Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT05167994 -
Preoperative IMRT With Concurrent Anlotinib for Localised Extremity or Trunk Sarcoma
|
Phase 2 | |
Recruiting |
NCT04684017 -
Anlotinib Plus Etoposide and Carboplatin as First-line Treatment for Extensive-stage Small Cell Lung Cancer
|
Phase 2 | |
Not yet recruiting |
NCT04665609 -
Thermal Ablation Combined With Anlotinib and TQB2450 Solution for HCC
|
Phase 3 | |
Not yet recruiting |
NCT05778149 -
Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation
|
Phase 2 | |
Recruiting |
NCT05311579 -
Niraparib Plus Anlotinib for Recurrent Ovarian Cancer
|
Phase 2 | |
Active, not recruiting |
NCT05400070 -
Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC
|
Phase 2 | |
Not yet recruiting |
NCT04807166 -
Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer
|
Phase 2 | |
Completed |
NCT04271813 -
Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC)
|
Phase 2 | |
Completed |
NCT04002284 -
Anlotinib in Metastatic HER2 Negative Breast Cancer
|
Phase 2 | |
Recruiting |
NCT04278222 -
Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric or Gastro-esophageal Junction Cancer (APICAL-GE)
|
Phase 2 | |
Recruiting |
NCT04757779 -
A Single-arm, Phase Ⅱ Clinical Trial of Anlotinib Hydrochloride Combined With Irinotecan or Docetaxel for Second Line Treatment of Nonsensitive Relapsed Small-cell Lung Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02072031 -
Phase II Study of Anlotinib Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma(RCC)
|
Phase 2 | |
Not yet recruiting |
NCT03589950 -
Anlotinib Plus Chemotherapy for Patients With Advanced Non-small Cell Lung Cancer
|
Phase 2 |